Linezolid-related pancytopenia in organ-transplant patients: report of two cases.
Linezolid is a recent oral antibiotic used in drug-resistant Gram-positive cocci infection. We herein report on the first two cases of linezolid-related pancytopenia in organ-transplant patients. Both patients had methicillineresistant Staphylococcus aureus infections. Pancytopenia, i.e. aregenerative anemia, neutropenia and thrombopenia, developed 3 weeks and 5 weeks after initiating linezolid therapy at a conventional dosage (600 mg bid). There were no other confounding causes of pancytopenia, which resolved promptly after withdrawing linezolid. Because of the potential hazards of pancytopenia in immunosuppressed organ-transplant patients, we advocate the cautious use of linezolid for transplant patients.
Faguer
S
S
Multiorgan Transplant Unit, University Hospital, CHU Rangueil, Toulouse, France.
Kamar
N
N
Fillola
G
G
Guitard
J
J
Rostaing
L
L
D000081:Acetamides / Q000009:adverse effects*; D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000009:adverse effects*; D010198:Pancytopenia / Q000139:chemically induced*; D010538:Peritonitis / Q000188:drug therapy* / Q000382:microbiology; D003668:Pressure Ulcer / Q000188:drug therapy* / Q000382:microbiology; D019737:Transplants / Q000009:adverse effects
D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid